Nuveen Asset Management, LLC Cue Biopharma, Inc. Transaction History

Nuveen Asset Management, LLC

$345 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.77 - $3.09 $80,021 - $139,698	-45,210 Reduced 23.6%	146,326 $276,000
Q3 2023 Nov 14, 2023	BUY	$2.23 - $4.69 $100,818 - $212,034	45,210 Added 30.9%	191,536 $440,000
Q2 2023 Aug 14, 2023	BUY	$3.11 - $4.91 $455,073 - $718,460	146,326 New	146,326 $534,000
Q2 2022 Aug 15, 2022	SELL	$2.49 - $5.92 $292,144 - $694,575	-117,327 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.41 - $12.28 $149,966 - $417,593	34,006 Added 40.81%	117,327 $659,000
Q4 2021 Feb 14, 2022	SELL	$10.86 - $17.85 $121,870 - $200,312	-11,222 Reduced 11.87%	83,321 $868,000
Q3 2021 Nov 12, 2021	SELL	$10.06 - $15.3 $17,122 - $26,040	-1,702 Reduced 1.77%	94,543 $1.22 Million
Q2 2021 Aug 16, 2021	SELL	$10.9 - $14.53 $70,021 - $93,340	-6,424 Reduced 6.26%	96,245 $1.12 Million
Q1 2021 May 17, 2021	SELL	$11.2 - $16.09 $444,550 - $638,644	-39,692 Reduced 27.88%	102,669 $1.25 Million
Q4 2020 Feb 16, 2021	BUY	$11.12 - $16.4 $10,130 - $14,940	911 Added 0.64%	142,361 $1.78 Million
Q3 2020 Nov 16, 2020	SELL	$15.05 - $23.54 $50,989 - $79,753	-3,388 Reduced 2.34%	141,450 $2.13 Million
Q2 2020 Aug 14, 2020	BUY	$12.7 - $30.73 $740,143 - $1.79 Million	58,279 Added 67.33%	144,838 $3.55 Million
Q1 2020 May 14, 2020	SELL	$9.85 - $22.27 $435,567 - $984,779	-44,220 Reduced 33.81%	86,559 $0
Q4 2019 Feb 14, 2020	BUY	$7.06 - $17.47 $429,424 - $1.06 Million	60,825 Added 86.95%	130,779 $2.08 Million
Q3 2019 Nov 14, 2019	BUY	$6.78 - $9.28 $44,781 - $61,294	6,605 Added 10.43%	69,954 $590,000
Q2 2019 Aug 15, 2019	BUY	$7.18 - $9.65 $454,845 - $611,317	63,349 New	63,349 $570,000

Others Institutions Holding CUE

# of Institutions

Shares Held

14.1M

Call Options Held

14.4K

Put Options Held

2.6K

View Full List

About Cue Biopharma, Inc.

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

More about CUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account